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Protease resistance and binding of Ig light chains in myeloma-associ-
ated tubulopathies. Kidney tubule dysfunction and lesions are frequent
complications of myeloma, related to unknown properties of the mono-
clonal light chain. We have analyzed protease sensitivity and binding
properties of urinary light chains from four patients with Fanconi's
syndrome, 12 with cast nephropathy, and four control patients without
myeloma-associated tubulopathy. All light chains were normal-sized,
monomeric and/or dimeric, and none was N-glycosylated. Kinetic studies
of light chain digestion by pepsin and the lysosomal enzyme cathepsin B
showed the generation of a protease-resistant 12 kDa fragment, corre-
sponding to the V domain of the K chain in the four Fanconi's syndrome
patients; in two out of four the V domain was also completely resistant to
trypsin. Western and dot blots revealed similar patterns of reactivity of
light chains from patients with the Fanconi's syndrome towards other light
chains. Properties of cast-nephropathy light chains were more heteroge-
neous but clearly differed from those of Fanconi's syndrome: (i) 9 out of
12 were of the A-type; (ii) only four yielded a transient 12 kDa fragment
after cathepsin B digestion, but all showed some resistance to proteolysis
of the entire molecule or a fragment thereof to at least one protease, at
variance with control light chains; (iii) they displayed various patterns of
reactivity with other light chains; (iv) 7 out of 12 reacted specifically with
Tamm-Horsfall protein (THP) by ELISA, in contrast with those of
Fanconi's syndrome. In one patient who presented with cast nephropathy
and the Fanconi's syndrome, the light chain exhibited both partial
resistance of the VK domain to cathepsin B and the highest reactivity with
THP. These results suggest that light chain toxicity in Fanconi's syndrome
is related to the resistance of the V domain to degradation in lysosomes of
proximal tubule epithelial cells. In contrast, cast nephropathy is an
heterogeneous entity whose pathogenesis may involve multiple factors
such as protease resistance, in addition to light chain reactivity with THP.
Kidney tubule alterations related to monoclonal immunoglob-
ulin (Ig) light chains are frequent complications of myeloma (1
case out of 3) [1]. They often lead to end-stage renal failure and
may thus be considered as severe prognosis factors. The most
common form is myeloma cast nephropathy, in which character-
istic lesions consist of tubular atrophy associated with the pres-
ence of dense fractured casts surrounded by macrophagic cells
predominantly located in the lumina of distal tubules and collect-
ing ducts [2]. Formation of these casts, which mainly contain the
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light chain together with Tamm-Horsfall protein (THP) and few
other protein components, is likely to be a major pathogenetic
factor of renal impairment through tubular obstruction. Renal
failure is also caused by associated lesions of tubule epithelial cells
which are usually considered to be the result of light chain toxicity
on the renal tubule [3].
Fanconi's syndrome is defined by specific alterations of proxi-
mal tubule functions, and may also complicate myeloma in rare
instances [4—6]. Myeloma-associated Fanconi's syndrome is gen-
erally featured by crystal inclusions in proliferating plasma cells,
macrophages and proximal-tubule epithelial cells. Although the
light-chain content of the intracellular crystals has long been
suggested by immunoperoxidase studies [7], we recently demon-
strated in one case that their predominant component was a 107
amino acid fragment corresponding precisely to the variable
domain of the light chain resistant to proteolysis and prone to
crystallization [8]. Intracellular protein crystals may also be found
in the tubules of patients with "classical" cast nephropathy [9],
which suggests that Fanconi's syndrome and cast nephropathy
could share common pathogenetic factors.
Intrinsic properties of light chains are likely to play a key
pathogenetic role in myeloma tubulopathies as evidenced by lack
of correlation between the amount of urinary light chain and renal
lesions, improvement of renal function after antitumoral chemo-
therapy [10—12] and recurrence on grafted kidney [13]. Moreover,
injection of pathogenic purified human light chains to mice [14,
15], as well as their infusion into rat renal tubules [16], induce the
generation of myeloma casts or of crystals comparable to those
found in the biopsy specimens. The lambda isotype may be more
frequently responsible for cast nephropathy than the kappa [11],
whereas the kappa isotype is usually involved in Fanconi's syn-
drome [5, 6], but these restrictions are far from being absolute [7].
Other structure-related properties, such as high isoelectric point
of the light chains, have been thought to influence their propensity
for interacting with THP and forming casts [17]; however, contra-
dictory results question this hypothesis [11, 18, 19].
In the present study, we purified monoclonal light chains from
12 patients with cast nephropathy and from four with the Fanco-
ni's syndrome. We showed that biochemical properties of light
chains, that is, binding to THP and resistance to proteases, were
not uniform in cast nephropathy patients who made up a heter-
ogeneous group both clinically and histologically. In contrast,
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Table 1. Characteristics of Fanconi's syndrome at initial presentation or biopsy time
Blood Urine
Calcium Phosphate Uric acid Glucose Amino
Patient m mivi I.M HC03 mmol/24 hr aciduria Bone lesions
FS1 2.14 0.96 135 23.6 +++ 7 Osteomalacia,
fractures
FS2 2.4 0.47 176 25 15 7 None
FS3 2.3 1.24 101 22 10 7 Osteoporosis
FS4 1.66 1.02 259 15 ++ 7 Osteoporosis
a Normal range is 215 to 375 jiM
Table 2. Clinical and biological data at the time of renal biopsy
Gender!
M component
Urine Marrow
Polymerisation Amount plasma cells Tumor
Serum
creatinine Course of renal
Patient Age Serum LC form g124 hr % mass jiM failure
FS1 F165 — K DIM 1.9 (60%) 2 low 168 Progressive
F52 MI42 IC K DIM 1.0 (50%) 9 low 274 Progressive
FS3 F186 K K DIM 0.8 (80%) 6 low 200 Progressive
FS4 M171 GK K DIM 1.7 (50%) 7.5 low 428 Progressive
CN1 FI72 AA A D 2.0 (90%) 86 high 2840 Irreversible
CN2 M160 A A DIM 2.7 (78%) 42 high 805 Partially reversible
CN3 M162 A A DIM 1.0 (60%) 18 high 1400 Irreversible
CN4 M166 DA A M 4.0 (80%) 20 low 130 Stable
CN5 M169 AA A DIM 7.5 (86%) 61 high 164 Irreversible
CN6 M133 GA A M 5.8 (95%) 64 high 1575 Reversible
CN7 M174 GA A DIM 2.4 (84%) 36 high 768 Irreversible
CN8 M171 GA A D 0.4 (60%) 7 high 945 Partially reversible
CN9 F157 K K D or M 9.1 (80%) 65 high 141 Reversible
CN1O F167 GA A D,P 4.1 (90%) 15 high 220 Irreversible
CN11 M134 K K M 3.1 (89%) >90 high 698 Irreversible
CN12 M147 GK K M 3.0 (87%) >50 high 812 Irreversible
FS, Fanconi's syndrome; CN, cast nephropathy; LC, light chain (Figures in brackets relate to % of LC M component in proteinuria); D, dimeric; M,
monomeric (DIM means that the two polymerization forms could not be separ4ted by chromatography); P, polymeric.
patients with the Fanconi's syndrome displayed remarkable clin-
ical, histological and biochemical similarities, with their light
chains being distinguished by prolonged resistance of the variable
domain (VIC) to proteolysis by pepsin and cathepsin B.
Methods
Patients
Characteristics of patients are depicted in Tables 1 to 3.
Patients FS1 to FS4 presented with the main aspects of the
Fanconi's syndrome (Table 1) including generalized aminoacid-
uria, glycosuria, and low or normal serum phosphate and uric acid
levels despite mild to severe but progressive renal insufficiency.
Typical osteomalacic bone lesions were seen in patient FS. Bone
X-rays were more difficult to interpret in the older patients (FS3
and FS4). The four patients with the Fanconi's syndrome had a
K-chain-secreting smoldering myeloma (Table 2).
In contrast, all patients except one with cast nephropathy were
affected with a high tumor mass myeloma producing A chains in 9
of them (Table 2). They also differed by higher amount of
proteinuria and more severe and acute renal failure. The search
for an associated Fanconi's syndrome was made difficult by
markedly deteriorated renal function in most patients. Only
patient CN9 showed the main signs of Fanconi's syndrome
including glycosuria (3 glday), generalized aminoaciduria, by-
pokaliemia (2.9 mEqlliter) and increased uric acid (27 mllmin)
and phosphate clearance (27 mllmin) despite decreased creatinine
clearance (37 mI/mm). Significant amounts of glycosuria were also
detected in patient CN1 who had corticosteroid-induced hyper-
glycemia, and in patient CN4 with a type-2 diabetes.
Renal biopsies of the four Fanconi's syndrome patients showed
severe epithelial lesions with crystal formations observed in three
cases in the cytoplasm of proximal tubule epithelial cells (Table
3). Casts were absent or hyaline, without features of myeloma
casts. FS2 and FS3 were remarkable by the abundance of crystals
in proximal tubule cells and their association with crystal inclu-
sions in interstitium infiltrating cells.
Biopsies from patients with cast nephropathy all contained
typical fractured myeloma casts showing polychromatism upon
staining with Masson's trichrome, and the casts were surrounded
by multinucleated giant cells. Crystals were only occasionally
detected within casts and in the cytoplasm of proximal and distal
tubule cells (CN6 and CN9, Table 3). The biopsy from CN6
showed multiple fractured, bulky crystalline casts in the tubular
lumina. Smaller crystals were present in phagolysosomes of distal
tubule cells. Multiple crystalline casts with a variety of appear-
ances were also found in CN9. This case was unusual in that
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Table 3. Histological findings in patients with myeloma-associated tubulopathies
GIomeruli % Tubules
Interstitium
Patient
Global
scler
.
Periglom
scler Crystals
.
Epith
lesions
Tubule
atrophy Castsa Fibrosis Crystals'
FS1 70 19 — +++ +++ Hyaline +++ —
FS2 60 10 +++ (Ep.) +++ + Hyaline + +
FS3 NA NA +++ (Ep.) +++ ++ None ++ +
FS4 50 9 ++ (Ep.) +++ +++ Hyaline +++ —
CN1 0 30 0 ++ ++ ++ ++ —
CN2 20 10 0 ++ + ++ ++ —
CN3 0 20 0 ++ ++ ++ ++ —
CN4 10 0 0 + + + + —
CN5 40 10 0 ++ ++ ++ + —
CN6 0 0 + (Casts) ++ 0 ++ 0 —
CN7 45 27 0 ++ + ++ ++ —
CN8 7 14 0 +++ + ++ ++ —
CN9 5 5 + (Casts+Ep.) ++ + ++ + —
CNIO 20 20 0 +++ 0 ++ 0 —
CN11 30 0 0 ++ 0 ++ 0 —
CN12 0 0 0 ++ 0 ++ + —
Abbreviations are: Global scler, global sclerosis; Periglom scler, periglomerular sclerosis; (Ep.), crystals in proximal tubule epithelial cells; Epith
lesions, epithelial lesions; NA, not available.
a Typical myeloma casts were seen only in patients with cast nephropathyb Presence of crystal inclusions in interstitium infiltrating cells
Table 4. Clinical and histological characteristics of control patients
Patients
Gender
age
M corn
Serum
ponent
Urine
Marrow
plasma
cells %
Tumor
mass
Serum
creatinine
si Renal biopsy
Type of
plasma cell
dyscrasia Comments
Cl M/76 GK ic 23 High 187 Nonspecific CIN Myeloma
C2
C3
F/64
M/81
GK
K
c
K
?
15
High
Low
N°
Dialysis"
ND
AIN with
eosinophils
Myeloma
Myeloma Type 2 diabetes
Diamicron-
induced AIN"
C4 F/79 A A 7 — 260 AL (A) amyloid "Primary" AL
amyloidosis
Nephrotic syndrome
Abbreviations are: ND, not done; CIN, chronic interstitial nephritis; AIN, acute interstitial nephritis.
a Normal renal function over 6 years
Recovery of renal function after stopping Diamicron"
proximal tubular cells were stuffed with similar crystals located in
distended phagolysosomes.
No patient had giomerular lesions related to amyloid or depo-
sition of light chains, but most had nonspecific globally sclerotic
glomeruli, probably as a consequence of tubulointerstitial and
vascular lesions.
Controls
Four control patients were also included in this study (Table 4).
The first three had a multiple myeloma. Cl presented with
nonspecific chronic interstitial nephritis. C2 did not develop renal
failure over a 6-year follow-up. A diagnosis of DiamicronTM
induced acute interstitial nephritis was made in C3 who rapidly
recovered a normal renal function after eviction of the drug. The
fourth control patient (C4) had "primary" AL amyloidosis with-
out evidence of myeloma.
Light chain purification
Urine samples were concentrated by dialysis under reduced
pressure and proteins were purified by a combination of DEAE-
Trisacryl (Sepracor, Villeneuve la Garenne, France) chromatog-
raphy in 10 mrvi Tris (pH 7.6 to 8 according to the light chain) with
a 0 to 0.3 M NaCl linear gradient, and gel filtration on Sephadex
G100, G150 or G200 Superfine (Pharmacia, Uppsala, Sweden).
Fractions were concentrated as above and purity was controlled
by thin layer agarose electrophoresis (Beckmann, Brea, CA,
USA), immunoelectrophoresis and 12% sodium dodecyl sulfate
polyacrylamide gel electrophoresis (SDS-PAGE).
N-glycosylation
N-glycosylation was searched for by treatment with endoglyco-
sidase-F (Boehringer, Manheim, Germany) after denaturation of
the light chain in 0.1% SDS at 100°C during two minutes and
dilution in 0.5% nonidet P40, 0.1 M Tris pH 8.3; after a two hours
incubation at 37°C with the enzyme (2 units per mg light chain),
samples were analyzed by 12% SDS-PAGE in comparison with
the native substrate.
Protease treatment
Pepsin (Boehringer) digestion of light chains (3 mg/mI) was
performed at 37°C in 50 mt glycine pH 3.5, with an enzyme
substrate ratio of 1:250. Light chains were similarly digested with
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tiypsin (Gibco, Paisley, UK) in 0.1 NI NaC1, 50 mi TRIS, pH 8.2
with an enzyme substrate ratio of 1:50. Digestion by cathepsin B
(Sigma, St. Louis, MO, USA) was performed at 37°C on 1 mg/mI
light chain solutions in 80 m sodium acetate, 8 mrvi L-cysteine,
pH 5.0 (0.33 units for 10 g light chain). The reaction was stopped
by 10 mi iodoacetamide. After various incubation times from ito
24 hours, samples were diluted in SDS-PAGE sample buffer and
frozen. When protease resistance was still detected at 24 hours of
enzymatic treatment, digestions were also extended to 48 hours.
Fifteen percent SDS-PAGE were stained by Coomassie R250
brilliant blue or electrotransferred onto nitroceliulose. Blots were
saturated by 5% skimmed milk and revealed by biotinylated
anti-kappa constant region (CK) monoclonal antibody (clone
HP6053, a gift of Dr. G. Carlone, CDC, Atlanta, GA, USA),
followed by alkaline phosphatase-conjugated streptavidin (Amer-
sham International, Amersham, UK).
Biotinylation
Samples (light chain and anti-CK antibody) were diluted to 1
mg/mi in 0.1 M sodium carbonate and incubated two hours at
room temperature with 10 tg/ml sulfosuccinimidyl-6-(biotin-
amido) hexanoate (Pierce, Rockford, IL, USA). The reaction was
stopped by adding 10% 1 M NH4CI. Biotinylated products were
purified on Sephadex G25 columns, and tested by a Western blot
revealed with streptavidin-peroxidase; their concentration was
evaluated by their absorbance at 280 nm (E11 cm = 14.0).
Light chain cross-reactivity
One microliter of each purified light chain (20 mg/ml) was
deposited on nitrocellulose sheets, then saturated as above,
incubated in biotinylated light chain solutions at 10 xg/ml in 2%
bovine serum albumin (BSA)-PBS and revealed with streptavidin-
peroxidase (Amersham).
Significant reactions of biotinylated light chains on dot blots
were controlled by a Western blot technique: 20 jxg of the
corresponding light chain were migrated by thin layer agarose
electrophoresis and transferred onto a nitrocelluiose sheet by a
single 10 minute pressure of 15 g/cm2. Blots were saturated and
revealed with biotinylated light chain as above.
Analysis of binding to Tamm-Horsfall protein (THP) by ELISA
Wells were coated overnight at 4°C with THP (2 jxg/100 pi in
PBS) or PBS alone as a control, then saturated with 2% BSA in
PBS for one hour at room temperature. Biotinylated albumin (A),
transferrin (T) and purified light chain (2.5 jxg/i00 d) from each
patient were incubated simultaneously in the same microplate for
two hours at room temperature, followed by streptavidin-peroxi-
dase (1:1000, 2 hr at room temperature). Enzymatic activity was
revealed by 1 mg/mI 0-phenylenediamine in 0.2 M citric acid, 0.2
NI tn-sodium acetate 0.03% H2O2. The reaction was stopped by
adding 1 N H2S04 and read at 450 nm with a Titertek Multiskan
spectrophotometer.
Simultaneously, specific binding of each light chain was as-
sessed by preincubating an excess of non-biotinylated light chain
(250 jxg/100 .d for 2 hr at room temperature) before adding the
biotinylated one.
Results were expressed as percentage of binding of CN1, the
light chain with maximal binding to THP (mean SEM of 6
experiments). Specificity of binding was established by statistical
comparison of values obtained in the absence and in the presence
of an excess of non-biotinylated light chain, using the Student's t
test.
Results
Light-chain purification and analyzes
Most purified light chains were mixtures of dimeric and/or
monomeric forms, as shown by SDS-PAGE under non-reducing
conditions (Table 2). In one case (CN9), we could completely
separate monomeric and dimeric fractions. All light chains were
normally sized and none was N-glycosylated, as suggested by
absence of migration shift on SDS-PAGE after treatment with
endoglycosidase F (not shown).
Protease treatment
In all cases of Fanconi's syndrome, studies of protease digestion
showed the generation of a 12 kDa fragment which was resistant
to further digestion by pepsin (Table 5) and cathepsin B (Fig. 1);
in two out of four cases, the fragment was also resistant to trypsin
(Table 5). After 48 hours of incubation, the amount of fragment
remained unchanged. Western blot analysis with anti-C mono-
clonal antibody suggested that these fragments corresponded to
the light chain variable regions (Fig. 1).
Light chains from all patients with cast nephropathy were
normally digested by cathepsin B, except for four: CN8 (Fig. 1) to
CN1 1 yielded small amounts of a 12 kDa fragment, but the latter
was only partially resistant since it was no longer observed at 48
hours of digestion. In addition, the entire light chain from 10
patients with cast nephropathy showed significant resistance to
trypsin and/or pepsin, but in only one case (CN11) was generated
a 12 kDa fragment totally resistant to pepsin (Table 5).
In the four control patients, no light chain resistance was
Table 5. Light chain resistance to protease treatment
Trypsin Pepsin Cathepsin B
Entire Entire Entire
light 12 kDa light 12 kDa light 12 lçDa
Protein chain fragment chain fragment chain fragment
Cl - - — - - -
C2 - — - — -
C3 - - - - - -
C4 - - - - - -
FS1 — — — ++ — ++
FS2 — ++ — ++ — ++
FS3 — — — ++ — ++
FS4 — ++ — ++ — ++
CN1 + — + — - -
CN2 + + + — — —
CN3 + + — + — —
CN4 - - ++ — - -
CN5 + — — - -
CN6 + — ++ — —
CN7 + — - -
CN8 + - -
CN9 - - - - +
CN1O — — + — — +
CN11 — — — ++ — +
CN12 - - + - - -
Symbols are: —, lack of +resistance; , partial resistance (defined
persistence of the entire LC or its 12 kDa fragment up to 24 hr
digestion); + +, complete resistance (over 48 hours of digestion).
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Fig. 1. 15% SDS-PAGE and Western blot analyzes of cathepsin B digestion products. The 4 K light chains purified from patients with Fanconi's syndrome
(FS1, FS2, FS3, FS4) as well as 2 light chains purified from patients with cast nephropathy (CN8=A, CNI2= K) were submitted to 15% SDS-PAGE (Left
panel) before (—) and after a 24 hour digestion with cathepsin B (+). Molecular weight markers (Pharmacia) were migrated in the left lane. Western
blot (Right panel) was revealed by biotinylated anti-kappa monoclonal antibody HP 6053 followed by alkaline-phosphatase conjugated streptavidin.
Table 6. Light chain—light chain reactivity
LC: Immobilized Cl C2 FS1 FS2 FS3 FS4 CN1 CN2 CN3 CN4 CN5 CN6 CN7 CN8 CN9 CN1O CN11 CN12
Biotinylated
Cl — — — + — — + + — — — — — — — — —
C2 - - - - - - + - - - - - - - - - -
FS1 — — — + — — — + + — — — — — — — — —
FS2 — — + + — — + + — — — + — — — —
FS3 + — — + — — — + + — — — — — — — —
FS4 — — — — — — — + + — — — — — — — — —
CN1 - - - - - - - - - - - - - - - - -
CN2 - - - - - - - - - - - - - - - - - -
CN3 — — + + + — — — — — — — — — + — — —
CN4 — — + — + — — — — — — — — + — + —
CN5 - - - - - - - + - - - - — - - -
CN6 — — - — — + — — — — — — + — — —
CN7 - - - - - - - - - - - - + - - -
CN8 - - - - - - — - - - - - - - - - - -
CN9 - - - - - - - - + - - - - - - - - -
CN1O - - - - - — - - - - - - - - - -
CN11 — — — — — — + + — — — — — + — — —
CN12 - - - - - - - + - - - - - - - - -
observed. Only C3 showed transient appearance of the 12 kDa
fragment which completely disappeared by 24 hours.
Light chain reactivity
Western blot and dot blot experiments revealed similar patterns
of reactivity of light chains from the four Fanconi's syndrome
patients towards other light chains, especially immobilized FS2,
CN2 and CN3 (Table 6 and Fig. 2). Only FS2 showed self-
reactivity. Light chains from patients without the Fanconi's syn-
drome displayed various patterns of reactivity. Immobilized CN9
had the broadest reactivity with other cast nephropathy light
chains. Reactivity of the same immobilized and biotinylated light
chain was not identical, suggesting that the form of presentation
of the light chain could influence its reactivity. No significant
binding was observed with normal human serum or with a human
monoclonal IgG, in the same experimental conditions.
Binding to THP
Albumin, transferrin as well as control and Fanconi's syndrome
light chains did not bind significantly to THP. Seven light chains
from cast nephropathy patients bound to THP (Fig. 3). Binding
was specific since it could be significantly reduced by a preincu-
bation with an excess of the non-biotinylated homologous light
chain.
Discussion
In this work, we have investigated some physicochemical prop-
erties of myeloma light chains which might be responsible for
tubular lesions. We decided to analyze comparatively myeloma-
associated Fanconi's syndrome and cast nephropathy because
these two complications, although both affecting the renal tubule,
occur in different settings. As illustrated by our own series as well
CN 1
+
CN2
CN3
CN4
CN5
CN6
CN7
- I
CN1 CN2 CN3 CN1 CN2 CN3 CN1 CN2 CN3
CN8 A B C
A B C 0 E
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Fig. 2. Light chain-light chain reactivity studies. Binding of biotinylated light chain to light chain immobilized on nitrocellulose was analyzed by dot blot
(Left panel. 20 .rg of light chain deposited per spot) and Western blot experiments after thin layer agarose electrophoresis (Right panel. 20 g of light
chain deposited per lane). The object of the Western blot was to demonstrate that reactivity was specifically directed to the light chain (identified by
its electrophoretic mobility). CN1 to CN8 (left) and CN1 to CN3 (right) are immobilized light chains from patients with cast nephropathy. They were
reacted with 10 rWml of biotinylated light chain from patients with Fanconi's syndrome (A = FS1, B = FS2, C = FS3, D = FS4) or with cast
nephropathy (E = CN3).
as others, FS usually appears in the course of smoldering myeloma
with low tumor mass [61, whereas CN occurs early in patients with
high tumor mass [11]. This contrasting time-course as well as the
different pattern of clinical and pathological expression suggested
that distinct properties of light chains might be implicated.
All four patients with Fanconi's syndrome excreted K-type light
chains, both in dimeric and monomeric forms, which were re-
markable by their pattern of proteolytic resistance and their
reactivity with other light chains. The four light chains yielded,
after cathepsin B treatment, a 12 kDa fragment which was
resistant to further proteolytic attack over a 48 hour period. This
fragment was most likely made of the K light chain variable region
(VK) as it was not recognized by an anti-C, antibody. Resistance
of the V domain to cathepsin B over 48 hours was specific for
Fanconi's syndrome i< chains. It was not observed with control or
cast-nephropathy light chains. A similar pattern of proteolysis was
noted with pepsin. These data confirm and extend a previous
single observation made on FS2 which, unlike four control K light
chains from myeloma patients without renal involvement, showed
resistance of its VK domain to trypsin and pepsin [8]; however,
cathepsin B sensitivity had not been evaluated in this initial study.
VK was the essential component of crystals forming spontaneously
from the patient's urine, and could also be crystallized alone using
the hanging drop technique [81. We now show that the same
proteolysis resistant fragment is specifically generated from four
different light chains by cathepsin B, an enzyme normally present
in lysosomes. This suggests that complete proteolysis cannot occur
in vivo after endocytosis of the light chain in proximal tubule
epithelial cells, leading to accumulation of the V fragment within
the cells in the lysosomal compartment.
A second characteristic of light chains from Fanconi's syndrome
is their peculiar proneness to react with other light chains.
Although self-reactivity of FS2 [8] was not verified with the other
three light chains, we did find an unusual pattern of reactivity
characterized by intense specific binding to immobilized FS2, CN2
and CN3 light chains. Since a low amount of polyclonal IgG is
continuously filtered through the glomerulus and then absorbed
by proximal tubule cells, reactivity of light chains with normal IgG
may serve as a nucleation starter for crystal formation. Alterna-
tively, this low affinity reactivity could merely reflect a restriction
of the V segment repertoire in light chains causing the Fanconi's
syndrome. Indeed, preliminary results show that they all belong to
the V,1 variability subgroup (Rocca et al, manuscript in prepara-
tion). In contrast, these chains did not show any reactivity with
THP, a protein absent from the proximal tubule.
It must be noted that cathepsin B resistance of the VK domain
was observed irrespective of the abundance of crystals in the
biopsy sample, suggesting that it is a common feature of Fanconi's
syndrome and possibly a more reliable marker than crystals
themselves. Accumulation of the V domain fragment generated
by lysosomal enzymes and favored by light chain reactivity may
alter apical membrane recycling and/or ATP production (hence
Na,K-ATPase functioning), as suggested by the presence of
mitochondrial lesions [5], leading to progressive impairment of
sodium-dependent apical transports. This hypothesis is currently
being investigated in our laboratory using proximal cell culture
models.
Physicochemical properties of cast nephropathy light chains
were more heterogeneous, but several common features contrast-
ing with those of Fanconi's syndrome are worth noting. (i) The
majority of light chains (9 of 12) were of the A-type. (ii) Only four
of them yielded a 12 kDa fragment after cathepsin B digestion,
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Fig. 3. Reactivity of light chains with Tamm-Horsfall protein (THP). Wells coated with THP were incubated with biotinylated albumin (A), transferrin
(T), and light chains purified from 2 control (Cl, C2), 4 Fanconi's syndrome (FS1 to FS4), and 12 cast nephropathy (CN1 to CN12) patients. These
proteins were added simultaneously to the same microplate at the concentration of 2.5 jg/100 jd, in the absence (0) or in the presence () ofan excess(x 100) of the nonbiotinylated protein (see Methods for details). Results are the mean SEM of 6 experiments, and are expressed as the percent of
binding of the light chain with maximum reactivity (CN1). Specificity of binding was assessed by statistical comparison of values obtained in the absence
and in the presence of an excess of the nonbiotinylated protein. ***p < 0.001; ** < 0.01; * < 0.05.
but contrary to light chains from patients with the Fanconi's
syndrome, this fragment disappeared when digestion was pro-
longed over 24 hours. Only one of the four patients (CN9)
exhibited crystals in casts and proximal tubule epithelial cells. (iii)
Cast nephropathy light chains did not show self-reactivity, and
none of them reproduced the pattern of reactivity of FS light
chains with FS2, CN2 and CN3. (iv) Seven out of the 12 light
chains showed significant reactivity with THP, in keeping with
previous data by Sanders et al [16, 20, 21] supporting a role for
coaggregation of human light chains with THP in cast formation.
The same authors demonstrated that heterotypic aggregation of
THP and light chain was promoted by a common peptide segment
of THP, but the carbohydrate moiety of THP was also required,
perhaps facilitating homotypic aggregation of the glycoprotein
[20]. When separation of monomers and dimers could be achieved
(CN9), reactivity with THP of the dimer was higher than that of
the monomer, as was reactivity with other light chains (not
shown); this may point to the role of a pseudo-antibody formed by
association of light chain variable domains.
That 5 of 12 cast nephropathy light chains did not react with
THP by ELISA may be explained by low affinity of certain light
chains [20], but also suggests heterogeneity of pathogenetic
mechanisms leading to cast formation. Myeloma casts occasion-
ally do not stain for THP in human biopsies [22]. Moreover, in
some rat experimental studies, casts induced by human myeloma
light chains did not contain TUP for the first 24 hours after
injection [14]. These observations suggest that some light chains
may undergo homotypic aggregation or precipitation in the
absence of THP, as shown in vitro by Myatt et al [23]. On the other
hand, since in all studied cases of cast nephropathy, the light
chains displayed a complete or partial resistance of either the
entire molecule or a fragment thereof to at least one protease, we
hypothesize that resistance to light chain catabolism by urinary
and macrophage-released proteases might be a pathogenic factor.
In contrast, all tested control light chains in this and our previous
study [81 were completely digested by proteases.
It is worth noting that in patient CN9, who presented with cast
nephropathy and features of the Fanconi's syndrome including
accumulation of crystals inside proximal tubule epithelial cells, the
light chain exhibited both partial resistance of a 12 kDa fragment
to cathepsin B and the highest reactivity with THP. Such boundary
forms of myeloma-associated tubulopathies were already de-
scribed morphologically by Pirani and associates [9], who found
crystals in proximal tubule cells in 5 of 24 cast nephropathies. Our
data may provide a biochemical basis to these observations. It is
also of interest that, at variance with the four patients with "pure"
Fanconi's syndrome, CN9 had an overt myeloma with 65%
plasmocytes and a high tumor burden.
Cast nephropathy appears to be an heterogeneous entity as far
as clinical, pathological [9, 24, 25] and molecular aspects are
concerned. Its pathogenesis is complex, involving intrinsic prop-
erties of urinary light chains, concentration and carbohydrate
content of THP [16], and extrinsic precipitants which modify the
distal nephron milieu [26]. Elucidation of the different pathogenic
factors in correlation with pathological forms would require
studies on a larger group of patients. In contrast, myeloma-
associated Fanconi's syndrome is a rather homogeneous entity
characterized by prolonged resistance of the light-chain variable
20
Leboulleux et al: Light chains in myeloma tubulopathies 79
region to proteolysis whose consequences need to be further
investigated at the cellular level.
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